Sartorius Q2 Results Overview

Sartorius AG reported second‑quarter revenue of €912 million, falling short of the €932.9 million consensus. The shortfall stemmed from accounting for refunds of U.S. tariff levies that were invalidated by the Supreme Court; the company will compensate customers for previously paid surcharges, recording the adjustments as reductions to both cost of sales and revenue. Consequently, the shares of Sartorius AG declined more than 4% and its Paris‑listed unit, Sartorius Stedim Biotech SA, dropped 8% on the news.

The underlying EBITDA margin improved to 30.8%, 90 basis points above the 29.9% consensus, delivering underlying EBITDA of €281 million versus €279 million expected. Operational sales in constant currencies grew 7.9%, outpacing the 7.5% consensus estimate.

Segment Performance

  • Bioprocess Solutions (BPS), which contributes roughly 80% of group revenue, posted an EBITDA margin of 32.9% against the 31.9% expected and achieved 8.4% constant‑currency sales growth versus the 8.2% consensus.
  • Lab Products & Services (LPS) recorded a 21.7% EBITDA margin, beating the 20.7% forecast, and delivered 5.8% sales growth compared with the 4.3% consensus.
  • Adjusted earnings per share (EPS) for the group were €1.29, missing the consensus of €1.35.

Sartorius Stedim Biotech SA

The Paris‑listed unit generated revenue of €766 million, missing the €787.6 million consensus, though it posted 8% constant‑currency growth versus the 9% expected. EBITDA reached €246 million, surpassing the €242 million estimate, yielding a 32.1% margin against the 31% forecast. Adjusted EPS of €1.25 beat the consensus by 5.1%.

Guidance and Analyst Commentary

Management reaffirmed full‑year guidance of 5‑9% group sales growth with a margin slightly above 30%, and a 6‑10% growth target for Sartorius Stedim Biotech. Morgan Stanley maintained an “overweight” rating with a €300 target price, describing the quarter as “reassuring” after adjusting for the tariff refund, which it estimates could trim revenue by up to €40 million, with €14 million still payable. The firm expects the refund to place group and BPS sales growth toward the lower end of guidance, while LPS should sit around the midpoint.

Jefferies rated both stocks as “buy,” assigning target prices of €307 for Sartorius AG and €262 for Sartorius Stedim Biotech, and indicated that the confirmation of guidance should reassure investors. The earnings call is expected to focus on the durability of the Asia‑Pacific market—where H1 constant‑currency sales rose 12.1% to €419 million driven by a China recovery—and on equipment‑order visibility.

Regional Sales Breakdown (H1, constant‑currency)

  • Asia‑Pacific: up 12.1% to €419 million
  • EMEA: up 7.2% to €784 million
  • Americas: up 5.6% (excluding tariff‑compensation effects)

Analysts highlighted that underlying trends such as consumables growth above 9% and a return to equipment growth were more material than the headline revenue miss.